Products
Products
Explore our advanced sequencing products for turning complex molecular signals into high-confidence readouts across clinical testing, RNA quality control, and translational methylation programs.
NeuroLens®
Neuron Cell-Death Test
RNA Clarity™
RNA Vaccine QC
MethylMap™
Native-Read Methylation Sequencing
Older woman discussing a clinical diagnosis with a female doctor who is reviewing a tablet in a medical office.
Services
Services
End-to-end sequencing services supporting genomic, epigenomic, and transcriptomic analysis, from experimental design and assay development to bioinformatics, interpretation, and data delivery.
Applications
Applications
Explore how our products and services help solve difficult biological and genomic problems, from liquid biopsy signals to complex regions and emerging biomarker development.
Hard-to-Sequence Genes & Complex Regions
Liquid Biopsy cfDNA Analysis
Custom Multiomic Panel Development
Company
Company
Building the future of precision diagnostics through sequencing innovation, scientific rigor, and collaborative partnerships.
About Us
Team
Resources
Contact
  • Applications
  • Applications
    Telomeres, the protective caps at the end of our chromosomes, sit at the intersection of aging, cancer, and neurodegeneration research.
    Telomeres, the protective caps at the end of our chromosomes, sit at the intersection of aging.
    Research & Translation
    Biopharma Research
    Clinical Development
  • Company
  • Company
    Building the future of precision diagnostics through sequencing innovation, scientific rigor, and collaborative partnerships.
    About Us
    Team
Complex Biology.
Clearer Answers.
Clinical diagnostics and research services spanning methylation, RNA, long-read genomics, bioinformatics, and assay development.
Start A Project
An Integrated Model for Impact
Renew builds platforms with a single goal: Improve patient care. With proprietary sequencing technologies and specialized analytical workflows, we uncover biological signals that conventional approaches often miss.

Our integrated technology model, which combines these workflows with CAP/CLIA laboratory infrastructure, transforms these molecular insights into real-world healthcare impact.
Contact
Scientist in a white lab coat examining a small object in a bright laboratory setting.
Clinical Products and Solutions
Renew translates advanced molecular technologies into clinical diagnostics, research tools, and operational workflows.
Clinical Product
NeuroLens®
Blood-based liquid biopsy for detecting neuron- and glia-associated cfDNA signals linked to active neurodegeneration.
QC Product
RNA Clarity™
Native RNA sequencing workflow for multi-attribute RNA therapeutic characterization, QC, and lot release testing.
Solution
Methylation Solutions
Native DNA methylation workflows enabling broader epigenetic coverage and higher-fidelity methylation profiling.
Solution
Hard-to-Sequence Genes
Long-read DNA sequencing workflows for resolving complex variants, repeats, haplotypes, and structural variation.
Built. Measured. Applied.
AUC - Alzheimer's disease discrimination in multi-disease cohorts
Increased CpG coverage compared to the Illumina Array
Accuracy of long-read PGx panel for CYP2D6 of GIAB
Analytical Accuracy of cell classification for cfDNA diagnostic use cases
Regional methylation accuracy with targeted gDNA native-read sequencing
Chromosome arms covered for reliable arm-level telomere length estimates
June 18, 2026
Renew Advances Epigenetic Diagnostics Through Path Fertility’s NOA Guide
Path Fertility's NOA Guide is an epigenetic diagnostic designed to inform surgical decision-making for men with non-obstructive azoospermia (NOA). Renew serves as the clinical testing provider, supporting translation of advanced methylation biology into clinical practice.
Text Link
June 18, 2026
Renew Expands Targeted Multiomic Sequencing Through Agilent Collaboration
Through a co-marketing agreement, Direct Targeted Methylation Sequencing combines Agilent enrichment chemistries with Renew's native-read workflow. The program supports integrated analysis of genetic and epigenetic variation across targeted regions for translational research applications.
Text Link
June 18, 2026
Renew and Valinor Partner to Build Largest Clinical Multi-Omics Dataset for Neurology
A strategic collaboration with Valinor will generate one of the largest clinical multiomic datasets for neurological disease research. The partnership combines Renew's high-resolution data generation with Valinor's machine learning platform to support predictive model development.
Text Link
June 18, 2026
Renew and Oxford Nanopore Accelerate Methylation Sequencing Toward Clinical Use
In collaboration with Oxford Nanopore, Renew is advancing Direct Whole Methylome Sequencing, a native-read methylation product designed to address limitations of bisulfite sequencing and methylation arrays. The program highlights Renew’s ability to capture genome-wide methylation, sequence, and hydroxymethylation signals together for research and clinical applications.
Text Link

In The Press

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Working With The Best
Oxford Nanopore Technologies
Advancing Direct Whole Methylome Sequencing with Oxford Nanopore, a native-read approach designed to move methylation analysis beyond bisulfite sequencing and arrays.
Agilent Technologies
Agilent enrichment chemistries and Renew’s proprietary native-read workflow come together in Direct Targeted Methylation Sequencing to profile genetic and epigenetic variation in targeted regions.
Twist Bioscience
Custom hybridization panels developed with Twist support Oxford Nanopore-based long-read targeted sequencing for complex genomic regions and application-specific targets.
Boston Heart Diagnostics
A strategic distribution relationship with Boston Heart Diagnostics supports NeuroLens commercialization and expands the path for blood-based brain cell death testing in clinical care.
Discover Your Next Breakthrough
Discover More
Join For Updates
Success! Thank you for joining our newsletter.
Oops! Something went wrong while submitting the form.
© 2026 Renew Biotechnologies | All Rights Reserved